drugset / Trial / NCT01625000

Safety and Efficacy of MP-214 in Patients With Schizophrenia

NCT01625000

Phase 2/3 Completed 512 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.

Timeline

Start
2012-05
Primary completion
2015-08
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 3 mg Oral
Subject Cariprazine Small molecule 6 mg Oral
Subject Cariprazine Small molecule 9 mg Oral
Comparator Risperidone Other / unclassified 4 mg Oral

Indications